Elicit: Aflibercept as a VEGF Decoy Receptor
Aflibercept as a VEGF Decoy Receptor
What is aflibercept's mechanism as a soluble decoy receptor that binds VEGF-A and PlGF?
Aflibercept functions as a soluble decoy receptor by binding VEGF-A and PlGF with high affinity in 1:1 complexes, preventing these ligands from activating their native VEGFR1 and VEGFR2 receptors and thereby blocking downstream angiogenic signaling pathways.
Abstract
Aflibercept functions as a soluble decoy receptor composed of the second Ig domain of VEGFR1 and the third Ig domain of VEGFR2 fused to the Fc region of human IgG1. It binds all isoforms of human VEGF-A with subpicomolar affinity (Kd = 0.49-0.5 pM) and PlGF with low picomolar affinity (Kd = 38.9 pM for human PlGF-2), forming homogeneous 1:1 complexes with each VEGF dimer. This binding mechanism occludes both the amino acids necessary for VEGFR1/R2 binding and the heparin-binding site on VEGF165, preventing VEGF-A and PlGF from activating their native receptors. The association rate for aflibercept binding to VEGF-A is orders of magnitude faster than bevacizumab and ranibizumab, and unlike these antibody-based approaches, aflibercept also binds VEGF-B and PlGF, providing broader VEGF family inhibition.
By sequestering VEGF-A and PlGF from circulation, aflibercept suppresses phosphorylation of VEGFR1 and VEGFR2 and downstream pathways including PI3K/AKT/mTOR and ERK, resulting in reduced endothelial cell proliferation, migration, and permeability. The monomeric 1:1 complex formation distinguishes aflibercept from bevacizumab’s multimeric complexes and avoids platelet activation and increased Fcγ receptor binding. An unexpected mechanistic property is aflibercept’s glycosylation-dependent binding to galectin-1, an angiogenic factor independent of VEGF-A, representing a novel anti-angiogenic function beyond VEGF family antagonism.
Methods
We analyzed 10 sources from an initial pool of 200, using 7 screening criteria. Each paper was reviewed for 8 key aspects that mattered most to the research question.
Characteristics of Included Studies
Study Information
| Study | Year | Full Text Retrieved? | Study Type | Primary Focus |
|---|---|---|---|---|
| Binding and neutralization of | 2012 | Yes | In vitro binding study | Binding kinetics and biological activity comparison of aflibercept, ranibizumab, and bevacizumab |
| N. Papadopoulos et al. | 2012 | Yes | In vitro binding study | Binding kinetics and biological activity comparison of aflibercept, ranibizumab, and bevacizumab |
| H. Deissler et al. | 2014 | No | In vitro cell-based study | Capacity of aflibercept to counteract VEGF-stimulated abnormal behavior of retinal endothelial cells |
| Atsuhiro Kanda et al. | 2015 | Yes | In vitro and ex vivo study | Aflibercept trapping of galectin-1 in diabetic retinopathy |
| D. MacDonald et al. | 2016 | Yes | In vitro biochemical study | VEGF binding stoichiometry and immune complex formation comparison between aflibercept and bevacizumab |
| T. Torimura et al. | 2016 | No | In vitro and in vivo mouse model | Antiangiogenic and antitumor activities in hepatocellular carcinoma |
| F. Lazzara et al. | 2019 | No | In vitro and in vivo diabetic retinopathy model | Aflibercept regulation of retinal inflammation via PlGF/ERK pathway |
| T. Torimura et al. | 2011 | No | In vitro and in vivo mouse hepatoma model | Antiangiogenic mechanisms in hepatoma |
| P. Golik & K. Tońska | 2012 | No | Review/comparison | Biological principles comparison of monoclonal antibody vs decoy receptor approaches |
| Hoai-Thu Thai et al. | 2011 | Yes | Phase I pharmacokinetic study | Mechanism-based pharmacokinetic modeling of free and bound aflibercept |
Key Mechanistic Findings
- Primary mechanistic insights discovered: Aflibercept binds and neutralizes galectin-1, a non-VEGF family angiogenic factor.
- Novel aspects of the decoy receptor function: Aflibercept's interaction with galectin-1 is a novel anti-angiogenic function beyond VEGF-A antagonism.
- Clinical relevance of mechanistic properties: High affinity for VEGF-A and low immunogenicity contribute to therapeutic efficacy.
- Unexpected mechanistic findings: Aflibercept's ability to neutralize galectin-1 independently of VEGF-A.
- Implications for therapeutic efficacy based on mechanism: Enhanced efficacy due to broad anti-angiogenic activity.
- Outstanding mechanistic questions identified: Further investigation into the role of galectin-1 in diabetic retinopathy and aflibercept's interaction with other angiogenic factors.